Detalhe da pesquisa
1.
T cell immunotherapies engage neutrophils to eliminate tumor antigen escape variants.
Cell
; 186(7): 1432-1447.e17, 2023 03 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-37001503
2.
The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer.
Immunity
; 56(1): 93-106.e6, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36574773
3.
Nivolumab for mismatch-repair-deficient or hypermutated gynecologic cancers: a phase 2 trial with biomarker analyses.
Nat Med
; 30(5): 1330-1338, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38653864
4.
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma.
Cancers (Basel)
; 14(11)2022 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35681616
5.
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors.
Clin Cancer Res
; 28(18): 3990-4002, 2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35499569
6.
Increased p53 expression induced by APR-246 reprograms tumor-associated macrophages to augment immune checkpoint blockade.
J Clin Invest
; 132(18)2022 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36106631
7.
In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.
Nat Commun
; 13(1): 5312, 2022 09 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-36085288
8.
Isoform specific anti-TGFß therapy enhances antitumor efficacy in mouse models of cancer.
Commun Biol
; 4(1): 1296, 2021 11 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-34789823
9.
Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair-proficient Metastatic Colorectal Cancer.
Clin Cancer Res
; 27(8): 2200-2208, 2021 04 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33504552
10.
Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial.
J Immunother Cancer
; 8(1)2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32503949